Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial

J. Hauth, B. Sibai, S. Caritis, P. VanDorsten, M. Lindheimer, M. Klebanoff, C. MacPherson, M. Landon, R. Paul, M. Miodovnik, P. Meis, M. Dombrowski, G. Thurnau, S. Walsh, D. McNellis, J. M. Roberts, W. W. Andrews, R. Copper, J. Harger, M. CotroneoT. Kamon, B. M. Mercer, Risa Ramsey, B. Sibai, Y. A. Rabello, D. McCart, E. Mueller, G. Norman, M. Dombrowski, A. Millinder, S. Walsh, S. McCoy, S. Elder, N. Elder, B. Carter, V. Schneider, G. Thurneau, A. Meier, V. Minton, M. Swain, A. H. Moawad, P. Jones, J. D. Iams, S. Meadows, S. Brenner, B. A. Collins, R. B. Newman, S. G. Carter, R. Romero, V. Sabo, R. P. Bain, E. Thom, D. Johnson, M. L. Fischer, C. Catz, S. J. Yaffe

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

OBJECTIVE: The aim of the study was too determine whether, in a low- dose aspirin thai in high-risk pregnancies, a decrease in maternal serum thromboxane B2 level predicted improved pregnancy outcomes. STUDY DESIGN: This multicenter, randomized, double-blind trial included 2539 women, 1010 of whom had sufficient serum samples at enrollment and at 24 to 28 weeks' gestation, 34 to 38 weeks' gestation, or both to assess longitudinal changes in thromboxane B2 level and their effects on pregnancy outcomes. Women were randomly assigned between 13 and 26 weeks' gestation to receive daily aspirin (60 mg) or placebo. RESULTS: Overall and in all subgroups women assigned to receive aspirin had markedly lower maternal thromboxane B2 concentration values than did those assigned to receive a placebo (P= .0001). Changes in thromboxane levels were not, however, correlated with adverse pregnancy outcomes. Women with ≥50% reduction in maternal serum thromboxane B2 concentrations from baseline had occurrences of preeclampsia (P= .922), preterm birth (P = .375), small for gestational age neonates (P = .938), and grade III or IV intraventricular hemorrhage (P = 1.000) similar to those of women who had <50% reduction. Similar results were found for women with thromboxane B2 level decreases of <15 versus >15 ng/mL and women with thromboxane B2 level decreases to <10 versus ≥10, <5 versus ≥5, and <1 versus ≥1 ng/mL. Maternal thromboxane B2 concentrations at enrollment were also not predictive of adverse outcomes. CONCLUSION: Neither maternal serum thromboxane B2 concentrations at enrollment nor their subsequent reduction were predictive of adverse pregnancy outcomes in a low-dose aspirin trial.

Original languageEnglish (US)
Pages (from-to)1193-1199
Number of pages7
JournalAmerican Journal of Obstetrics and Gynecology
Volume179
Issue number5
DOIs
StatePublished - Jan 1 1998

Fingerprint

High-Risk Pregnancy
Thromboxane B2
Aspirin
Mothers
Pregnancy Outcome
Serum
Pregnancy
Placebos
Thromboxanes
Premature Birth
Pre-Eclampsia
Gestational Age
Newborn Infant
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial. / Hauth, J.; Sibai, B.; Caritis, S.; VanDorsten, P.; Lindheimer, M.; Klebanoff, M.; MacPherson, C.; Landon, M.; Paul, R.; Miodovnik, M.; Meis, P.; Dombrowski, M.; Thurnau, G.; Walsh, S.; McNellis, D.; Roberts, J. M.; Andrews, W. W.; Copper, R.; Harger, J.; Cotroneo, M.; Kamon, T.; Mercer, B. M.; Ramsey, Risa; Sibai, B.; Rabello, Y. A.; McCart, D.; Mueller, E.; Norman, G.; Dombrowski, M.; Millinder, A.; Walsh, S.; McCoy, S.; Elder, S.; Elder, N.; Carter, B.; Schneider, V.; Thurneau, G.; Meier, A.; Minton, V.; Swain, M.; Moawad, A. H.; Jones, P.; Iams, J. D.; Meadows, S.; Brenner, S.; Collins, B. A.; Newman, R. B.; Carter, S. G.; Romero, R.; Sabo, V.; Bain, R. P.; Thom, E.; Johnson, D.; Fischer, M. L.; Catz, C.; Yaffe, S. J.

In: American Journal of Obstetrics and Gynecology, Vol. 179, No. 5, 01.01.1998, p. 1193-1199.

Research output: Contribution to journalArticle

Hauth, J, Sibai, B, Caritis, S, VanDorsten, P, Lindheimer, M, Klebanoff, M, MacPherson, C, Landon, M, Paul, R, Miodovnik, M, Meis, P, Dombrowski, M, Thurnau, G, Walsh, S, McNellis, D, Roberts, JM, Andrews, WW, Copper, R, Harger, J, Cotroneo, M, Kamon, T, Mercer, BM, Ramsey, R, Sibai, B, Rabello, YA, McCart, D, Mueller, E, Norman, G, Dombrowski, M, Millinder, A, Walsh, S, McCoy, S, Elder, S, Elder, N, Carter, B, Schneider, V, Thurneau, G, Meier, A, Minton, V, Swain, M, Moawad, AH, Jones, P, Iams, JD, Meadows, S, Brenner, S, Collins, BA, Newman, RB, Carter, SG, Romero, R, Sabo, V, Bain, RP, Thom, E, Johnson, D, Fischer, ML, Catz, C & Yaffe, SJ 1998, 'Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial', American Journal of Obstetrics and Gynecology, vol. 179, no. 5, pp. 1193-1199. https://doi.org/10.1016/S0002-9378(98)70130-9
Hauth, J. ; Sibai, B. ; Caritis, S. ; VanDorsten, P. ; Lindheimer, M. ; Klebanoff, M. ; MacPherson, C. ; Landon, M. ; Paul, R. ; Miodovnik, M. ; Meis, P. ; Dombrowski, M. ; Thurnau, G. ; Walsh, S. ; McNellis, D. ; Roberts, J. M. ; Andrews, W. W. ; Copper, R. ; Harger, J. ; Cotroneo, M. ; Kamon, T. ; Mercer, B. M. ; Ramsey, Risa ; Sibai, B. ; Rabello, Y. A. ; McCart, D. ; Mueller, E. ; Norman, G. ; Dombrowski, M. ; Millinder, A. ; Walsh, S. ; McCoy, S. ; Elder, S. ; Elder, N. ; Carter, B. ; Schneider, V. ; Thurneau, G. ; Meier, A. ; Minton, V. ; Swain, M. ; Moawad, A. H. ; Jones, P. ; Iams, J. D. ; Meadows, S. ; Brenner, S. ; Collins, B. A. ; Newman, R. B. ; Carter, S. G. ; Romero, R. ; Sabo, V. ; Bain, R. P. ; Thom, E. ; Johnson, D. ; Fischer, M. L. ; Catz, C. ; Yaffe, S. J. / Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial. In: American Journal of Obstetrics and Gynecology. 1998 ; Vol. 179, No. 5. pp. 1193-1199.
@article{1938176de6ae4ecda7f44096ad15b402,
title = "Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial",
abstract = "OBJECTIVE: The aim of the study was too determine whether, in a low- dose aspirin thai in high-risk pregnancies, a decrease in maternal serum thromboxane B2 level predicted improved pregnancy outcomes. STUDY DESIGN: This multicenter, randomized, double-blind trial included 2539 women, 1010 of whom had sufficient serum samples at enrollment and at 24 to 28 weeks' gestation, 34 to 38 weeks' gestation, or both to assess longitudinal changes in thromboxane B2 level and their effects on pregnancy outcomes. Women were randomly assigned between 13 and 26 weeks' gestation to receive daily aspirin (60 mg) or placebo. RESULTS: Overall and in all subgroups women assigned to receive aspirin had markedly lower maternal thromboxane B2 concentration values than did those assigned to receive a placebo (P= .0001). Changes in thromboxane levels were not, however, correlated with adverse pregnancy outcomes. Women with ≥50{\%} reduction in maternal serum thromboxane B2 concentrations from baseline had occurrences of preeclampsia (P= .922), preterm birth (P = .375), small for gestational age neonates (P = .938), and grade III or IV intraventricular hemorrhage (P = 1.000) similar to those of women who had <50{\%} reduction. Similar results were found for women with thromboxane B2 level decreases of <15 versus >15 ng/mL and women with thromboxane B2 level decreases to <10 versus ≥10, <5 versus ≥5, and <1 versus ≥1 ng/mL. Maternal thromboxane B2 concentrations at enrollment were also not predictive of adverse outcomes. CONCLUSION: Neither maternal serum thromboxane B2 concentrations at enrollment nor their subsequent reduction were predictive of adverse pregnancy outcomes in a low-dose aspirin trial.",
author = "J. Hauth and B. Sibai and S. Caritis and P. VanDorsten and M. Lindheimer and M. Klebanoff and C. MacPherson and M. Landon and R. Paul and M. Miodovnik and P. Meis and M. Dombrowski and G. Thurnau and S. Walsh and D. McNellis and Roberts, {J. M.} and Andrews, {W. W.} and R. Copper and J. Harger and M. Cotroneo and T. Kamon and Mercer, {B. M.} and Risa Ramsey and B. Sibai and Rabello, {Y. A.} and D. McCart and E. Mueller and G. Norman and M. Dombrowski and A. Millinder and S. Walsh and S. McCoy and S. Elder and N. Elder and B. Carter and V. Schneider and G. Thurneau and A. Meier and V. Minton and M. Swain and Moawad, {A. H.} and P. Jones and Iams, {J. D.} and S. Meadows and S. Brenner and Collins, {B. A.} and Newman, {R. B.} and Carter, {S. G.} and R. Romero and V. Sabo and Bain, {R. P.} and E. Thom and D. Johnson and Fischer, {M. L.} and C. Catz and Yaffe, {S. J.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0002-9378(98)70130-9",
language = "English (US)",
volume = "179",
pages = "1193--1199",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial

AU - Hauth, J.

AU - Sibai, B.

AU - Caritis, S.

AU - VanDorsten, P.

AU - Lindheimer, M.

AU - Klebanoff, M.

AU - MacPherson, C.

AU - Landon, M.

AU - Paul, R.

AU - Miodovnik, M.

AU - Meis, P.

AU - Dombrowski, M.

AU - Thurnau, G.

AU - Walsh, S.

AU - McNellis, D.

AU - Roberts, J. M.

AU - Andrews, W. W.

AU - Copper, R.

AU - Harger, J.

AU - Cotroneo, M.

AU - Kamon, T.

AU - Mercer, B. M.

AU - Ramsey, Risa

AU - Sibai, B.

AU - Rabello, Y. A.

AU - McCart, D.

AU - Mueller, E.

AU - Norman, G.

AU - Dombrowski, M.

AU - Millinder, A.

AU - Walsh, S.

AU - McCoy, S.

AU - Elder, S.

AU - Elder, N.

AU - Carter, B.

AU - Schneider, V.

AU - Thurneau, G.

AU - Meier, A.

AU - Minton, V.

AU - Swain, M.

AU - Moawad, A. H.

AU - Jones, P.

AU - Iams, J. D.

AU - Meadows, S.

AU - Brenner, S.

AU - Collins, B. A.

AU - Newman, R. B.

AU - Carter, S. G.

AU - Romero, R.

AU - Sabo, V.

AU - Bain, R. P.

AU - Thom, E.

AU - Johnson, D.

AU - Fischer, M. L.

AU - Catz, C.

AU - Yaffe, S. J.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - OBJECTIVE: The aim of the study was too determine whether, in a low- dose aspirin thai in high-risk pregnancies, a decrease in maternal serum thromboxane B2 level predicted improved pregnancy outcomes. STUDY DESIGN: This multicenter, randomized, double-blind trial included 2539 women, 1010 of whom had sufficient serum samples at enrollment and at 24 to 28 weeks' gestation, 34 to 38 weeks' gestation, or both to assess longitudinal changes in thromboxane B2 level and their effects on pregnancy outcomes. Women were randomly assigned between 13 and 26 weeks' gestation to receive daily aspirin (60 mg) or placebo. RESULTS: Overall and in all subgroups women assigned to receive aspirin had markedly lower maternal thromboxane B2 concentration values than did those assigned to receive a placebo (P= .0001). Changes in thromboxane levels were not, however, correlated with adverse pregnancy outcomes. Women with ≥50% reduction in maternal serum thromboxane B2 concentrations from baseline had occurrences of preeclampsia (P= .922), preterm birth (P = .375), small for gestational age neonates (P = .938), and grade III or IV intraventricular hemorrhage (P = 1.000) similar to those of women who had <50% reduction. Similar results were found for women with thromboxane B2 level decreases of <15 versus >15 ng/mL and women with thromboxane B2 level decreases to <10 versus ≥10, <5 versus ≥5, and <1 versus ≥1 ng/mL. Maternal thromboxane B2 concentrations at enrollment were also not predictive of adverse outcomes. CONCLUSION: Neither maternal serum thromboxane B2 concentrations at enrollment nor their subsequent reduction were predictive of adverse pregnancy outcomes in a low-dose aspirin trial.

AB - OBJECTIVE: The aim of the study was too determine whether, in a low- dose aspirin thai in high-risk pregnancies, a decrease in maternal serum thromboxane B2 level predicted improved pregnancy outcomes. STUDY DESIGN: This multicenter, randomized, double-blind trial included 2539 women, 1010 of whom had sufficient serum samples at enrollment and at 24 to 28 weeks' gestation, 34 to 38 weeks' gestation, or both to assess longitudinal changes in thromboxane B2 level and their effects on pregnancy outcomes. Women were randomly assigned between 13 and 26 weeks' gestation to receive daily aspirin (60 mg) or placebo. RESULTS: Overall and in all subgroups women assigned to receive aspirin had markedly lower maternal thromboxane B2 concentration values than did those assigned to receive a placebo (P= .0001). Changes in thromboxane levels were not, however, correlated with adverse pregnancy outcomes. Women with ≥50% reduction in maternal serum thromboxane B2 concentrations from baseline had occurrences of preeclampsia (P= .922), preterm birth (P = .375), small for gestational age neonates (P = .938), and grade III or IV intraventricular hemorrhage (P = 1.000) similar to those of women who had <50% reduction. Similar results were found for women with thromboxane B2 level decreases of <15 versus >15 ng/mL and women with thromboxane B2 level decreases to <10 versus ≥10, <5 versus ≥5, and <1 versus ≥1 ng/mL. Maternal thromboxane B2 concentrations at enrollment were also not predictive of adverse outcomes. CONCLUSION: Neither maternal serum thromboxane B2 concentrations at enrollment nor their subsequent reduction were predictive of adverse pregnancy outcomes in a low-dose aspirin trial.

UR - http://www.scopus.com/inward/record.url?scp=0031756774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031756774&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(98)70130-9

DO - 10.1016/S0002-9378(98)70130-9

M3 - Article

C2 - 9822499

AN - SCOPUS:0031756774

VL - 179

SP - 1193

EP - 1199

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 5

ER -